Your browser doesn't support javascript.
loading
Potential Impact of IMbrave150 Results in the Evolving Treatment Landscape of Advanced Hepatocellular Carcinoma: A Multidisciplinary Expert Opinion.
Kulik, Laura; da Fonseca, Leonardo G; He, Aiwu Ruth; Rimola, Jordi; Wilson Woods, Andrea; Zöllner, York F; Galle, Peter R.
Affiliation
  • Kulik L; Northwestern University, Chicago, IL, USA.
  • da Fonseca LG; Clinical Oncology, Instituto do Cancer do Estado de São Paulo, São Paulo, Brazil.
  • He AR; Georgetown University, Washington, DC, USA.
  • Rimola J; Radiology Department, Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain.
  • Wilson Woods A; Blue Faery: The Adrienne Wilson Liver Cancer Association, Birmingham, AL, USA.
  • Zöllner YF; Hamburg University of Applied Sciences, Competence Center Health, Hamburg, Germany.
  • Galle PR; University Medical Centre Mainz, Mainz, Germany.
J Hepatocell Carcinoma ; 7: 423-433, 2020.
Article in En | MEDLINE | ID: mdl-33376711
A virtual expert roundtable was convened on April 16, 2020, to discuss the evolving landscape of care for treating patients with advanced hepatocellular carcinoma (HCC) and discuss questions related to patient care and treatment selection. This commentary presents highlights from this discussion and provides an expert opinion about approaches to treatment for HCC in the Americas and the European Union. We anticipate that atezolizumab plus bevacizumab will become the standard of care for advanced HCC patients. However, this approach will make decisions regarding the sequencing of treatments for second-line therapies and beyond more challenging. Therapy will require individualization based on patient characteristics and preferences, while insurance coverage decisions and requirements may also impact the options that patients can access. Additional research regarding prognostic and predictive biomarkers is needed to help better identify optimal treatment approaches for specific patient populations. Multidisciplinary tumor boards will continue to play a critical role in guiding treatment selection for individual patients. Atezolizumab plus bevacizumab offers a promising new first-line therapeutic option for patients with advanced HCC, but more research is needed to optimize and individualize patient therapy.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Aspects: Patient_preference Language: En Journal: J Hepatocell Carcinoma Year: 2020 Document type: Article Affiliation country: Estados Unidos Country of publication: Nueva Zelanda

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Aspects: Patient_preference Language: En Journal: J Hepatocell Carcinoma Year: 2020 Document type: Article Affiliation country: Estados Unidos Country of publication: Nueva Zelanda